Until now, very few studies showed the effect of QS inhibitors on CF clinical isolates (Rampioni et al., 2017b; D’Angelo et al., 2018; Baldelli et al., 2020; Mahan et al., 2020; Papa et al., 2021; Soukarieh et al., 2021), and only in one study the antivirulence activity of a drug targeting the las QS system, furanone C-30, was tested in a collection of fifty CF isolates, revealing highly variable response and high frequency of resistance to the QS inhibitor in CF isolates (García-Contreras et al., 2015), in overall accordance with this study. The gene discussed is LIAS; the disease is cystic fibrosis.